vs
Side-by-side financial comparison of CXApp Inc. (CXAI) and China SXT Pharmaceuticals, Inc. (SXTC). Click either name above to swap in a different company.
CXApp Inc. is the larger business by last-quarter revenue ($1.0M vs $829.5K, roughly 1.2× China SXT Pharmaceuticals, Inc.). China SXT Pharmaceuticals, Inc. runs the higher net margin — -96.8% vs -544.1%, a 447.4% gap on every dollar of revenue. On growth, China SXT Pharmaceuticals, Inc. posted the faster year-over-year revenue change (0.0% vs -38.5%). China SXT Pharmaceuticals, Inc. produced more free cash flow last quarter ($-1.8M vs $-3.6M).
CXApp Inc. is a technology firm specializing in digital workplace experience solutions. It offers cloud-based software tools for employee engagement, office space optimization, visitor management, and hybrid work coordination, serving mid-to-large enterprises across North America, APAC and Europe.
China SXT Pharmaceuticals, Inc. is a pharmaceutical company focused on the Chinese domestic market. It engages in the research, development, production and distribution of traditional Chinese medicine-based prescription drugs, over-the-counter medications, and nutritional health products, serving both clinical medical institutions and consumer health markets.
CXAI vs SXTC — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.0M | $829.5K |
| Net Profit | $-5.6M | $-802.6K |
| Gross Margin | 86.9% | 16.2% |
| Operating Margin | -576.9% | -76.9% |
| Net Margin | -544.1% | -96.8% |
| Revenue YoY | -38.5% | 0.0% |
| Net Profit YoY | -56.7% | 0.0% |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.0M | — | ||
| Q3 25 | $1.1M | $829.5K | ||
| Q2 25 | $1.2M | — | ||
| Q1 25 | $1.2M | — | ||
| Q4 24 | $1.7M | — | ||
| Q3 24 | $1.9M | $829.5K | ||
| Q2 24 | $1.8M | — | ||
| Q1 24 | $1.8M | — |
| Q4 25 | $-5.6M | — | ||
| Q3 25 | $-3.2M | $-802.6K | ||
| Q2 25 | $-3.1M | — | ||
| Q1 25 | $-1.6M | — | ||
| Q4 24 | $-3.5M | — | ||
| Q3 24 | $-5.4M | $-802.6K | ||
| Q2 24 | $-5.3M | — | ||
| Q1 24 | $-5.2M | — |
| Q4 25 | 86.9% | — | ||
| Q3 25 | 89.0% | 16.2% | ||
| Q2 25 | 86.0% | — | ||
| Q1 25 | 87.7% | — | ||
| Q4 24 | 86.0% | — | ||
| Q3 24 | 80.4% | 16.2% | ||
| Q2 24 | 80.0% | — | ||
| Q1 24 | 82.0% | — |
| Q4 25 | -576.9% | — | ||
| Q3 25 | -343.4% | -76.9% | ||
| Q2 25 | -336.1% | — | ||
| Q1 25 | -306.0% | — | ||
| Q4 24 | -169.7% | — | ||
| Q3 24 | -194.3% | -76.9% | ||
| Q2 24 | -206.7% | — | ||
| Q1 24 | -197.3% | — |
| Q4 25 | -544.1% | — | ||
| Q3 25 | -283.4% | -96.8% | ||
| Q2 25 | -256.7% | — | ||
| Q1 25 | -132.0% | — | ||
| Q4 24 | -213.6% | — | ||
| Q3 24 | -286.5% | -96.8% | ||
| Q2 24 | -297.6% | — | ||
| Q1 24 | -284.4% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-0.25 | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $11.1M | $18.1M |
| Total DebtLower is stronger | — | $105.0K |
| Stockholders' EquityBook value | $14.0M | $15.4M |
| Total Assets | $32.4M | $21.7M |
| Debt / EquityLower = less leverage | — | 0.01× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $11.1M | — | ||
| Q3 25 | $5.1M | $18.1M | ||
| Q2 25 | $4.9M | — | ||
| Q1 25 | $3.9M | — | ||
| Q4 24 | $4.9M | — | ||
| Q3 24 | — | $18.5M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | $105.0K | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $952.3K | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $14.0M | — | ||
| Q3 25 | $15.2M | $15.4M | ||
| Q2 25 | $14.3M | — | ||
| Q1 25 | $15.6M | — | ||
| Q4 24 | $15.6M | — | ||
| Q3 24 | $13.6M | $15.0M | ||
| Q2 24 | $16.3M | — | ||
| Q1 24 | $20.9M | — |
| Q4 25 | $32.4M | — | ||
| Q3 25 | $28.5M | $21.7M | ||
| Q2 25 | $29.6M | — | ||
| Q1 25 | $29.3M | — | ||
| Q4 24 | $31.8M | — | ||
| Q3 24 | — | $31.0M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.06× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-3.6M | $-1.4M |
| Free Cash FlowOCF − Capex | $-3.6M | $-1.8M |
| FCF MarginFCF / Revenue | -355.5% | -216.2% |
| Capex IntensityCapex / Revenue | 0.2% | 4.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-10.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-3.6M | — | ||
| Q3 25 | $-2.8M | $-1.4M | ||
| Q2 25 | $-3.0M | — | ||
| Q1 25 | $-979.0K | — | ||
| Q4 24 | $-2.7M | — | ||
| Q3 24 | $-2.1M | $-1.4M | ||
| Q2 24 | $-1.9M | — | ||
| Q1 24 | $-650.0K | — |
| Q4 25 | $-3.6M | — | ||
| Q3 25 | $-2.8M | $-1.8M | ||
| Q2 25 | $-3.0M | — | ||
| Q1 25 | $-984.0K | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-2.1M | — | ||
| Q2 24 | $-1.9M | — | ||
| Q1 24 | $-668.0K | — |
| Q4 25 | -355.5% | — | ||
| Q3 25 | -248.1% | -216.2% | ||
| Q2 25 | -247.2% | — | ||
| Q1 25 | -80.4% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -109.3% | — | ||
| Q2 24 | -108.6% | — | ||
| Q1 24 | -36.7% | — |
| Q4 25 | 0.2% | — | ||
| Q3 25 | 0.4% | 4.9% | ||
| Q2 25 | 0.9% | — | ||
| Q1 25 | 0.4% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.2% | — | ||
| Q2 24 | 0.5% | — | ||
| Q1 24 | 1.0% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
